Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 128,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Follow @Novartis at http://twitter.com/novartis.
Through our business, we make an important contribution to society: We discover and develop innovative healthcare products, targeting unmet medical needs.
Novartis works to reach more patients with access initiatives and affordability strategies for our medicines and vaccines, as well as targeted health education, particularly in the developing world. In 2012, our access programs reached more than 100 million patients globally. Millions more purchased high-quality, low-cost generics from our Sandoz Division. Learn more.
Focused on access, treatment, R&D and capacity building, the Novartis Malaria Initiative is one of the healthcare industry's largest access-to-medicine programs measured by the number of patients reached annually. Since 2001, working with a range of organizations, we have provided 500 million treatments for adults and children, without profit, to more than 60 malaria-endemic countries, contributing to a significant reduction of the death toll from malaria, mostly infants and children. Learn more.
From 2005 to 2012, Novartis has donated nearly 500,000 TB treatments to Tanzania. This donation is made available through the Global Drug Facility (GDF) of the Stop TB Partnership, which is hosted by the World Health Organization. Sandoz has a wide range of TB treatments developed in line with treatment guidelines of WHO and other National TB control programs. Learn more.
The Novartis Foundation for Sustainable Development (NFSD) works to improve the standard of health in developing countries by serving as a think tank and by initiating partnerships that improve access to health services, strengthen human resources in health and empower vulnerable groups. Learn more.
Arogya Parivar ("healthy family" in Hindi) is a for-profit social initiative developed by Novartis to help deliver healthcare to millions of people in rural India. Learn more.